Merck topped estimates and raised its profit forecast as cancer drug injection took off

Adjusted profit forecast moves to $2.77 to $2.82 a share from $2.66 to $2.76 as Keytruda Qlex sales reach $830 million

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (qz.com)